Chandra Prasad
1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
- Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells
- 2018
- WNT5A as a therapeutic target in breast cancer
- 2017
-
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model
Canesin, Giacomo LU ; Evans-Axelsson, Susan LU
;
Hellsten, Rebecka
LU
;
Krzyzanowska, Agnieszka
LU
;
Prasad, Chandra P.
LU
;
Bjartell, Anders
LU
and
Andersson, Tommy
LU
(2017)
In PLoS ONE
12(9).
Mark
- Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion
- 2016
- Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration.
- Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells
- WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition
- Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells : Dual interference of this loop more effectively impairs melanoma cell invasion
- 2015
- Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
- 2014
- Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression.